Drug
Aln Aat02
Aln Aat02: highest development phase Phase 1/2, developed by Alnylam Pharmaceuticals. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Alnylam Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| ALN-AAT02 NCT03767829 | Phase 1/2 | ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease |
Latest
No recent events.
Follow Aln Aat02 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.